Analysts Offer Predictions for Lexicon Pharmaceuticals, Inc.’s FY2019 Earnings (LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities researchers at Wedbush reduced their FY2019 earnings estimates for shares of Lexicon Pharmaceuticals in a research report issued on Thursday. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will post earnings per share of $0.66 for the year, down from their previous estimate of $0.74. Wedbush currently has a “Outperform” rating and a $38.00 target price on the stock. Wedbush also issued estimates for Lexicon Pharmaceuticals’ FY2020 earnings at $2.89 EPS.
Other analysts have also recently issued research reports about the company. Needham & Company LLC reissued a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, BidaskClub cut Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $28.50.
Shares of Lexicon Pharmaceuticals (NASDAQ LXRX) opened at $10.45 on Friday. Lexicon Pharmaceuticals has a 12-month low of $8.07 and a 12-month high of $18.00. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.07. The firm had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The business’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.35) earnings per share.
In related news, insider Lonnel Coats purchased 30,000 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, September 15th. The stock was bought at an average price of $12.54 per share, with a total value of $376,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Public Equities L.P. Invus purchased 575,946 shares of Lexicon Pharmaceuticals stock in a transaction on Tuesday, November 14th. The stock was bought at an average cost of $9.64 per share, with a total value of $5,552,119.44. The disclosure for this purchase can be found here. Insiders acquired 945,353 shares of company stock valued at $9,304,953 in the last ninety days. Insiders own 5.77% of the company’s stock.
Several large investors have recently made changes to their positions in LXRX. Vanguard Group Inc. lifted its position in shares of Lexicon Pharmaceuticals by 16.3% in the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock worth $59,773,000 after buying an additional 585,222 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Lexicon Pharmaceuticals by 1.0% in the first quarter. Geode Capital Management LLC now owns 433,420 shares of the biopharmaceutical company’s stock worth $6,215,000 after buying an additional 4,141 shares during the last quarter. Morgan Stanley lifted its position in shares of Lexicon Pharmaceuticals by 22.7% in the first quarter. Morgan Stanley now owns 174,765 shares of the biopharmaceutical company’s stock worth $2,505,000 after buying an additional 32,276 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the first quarter worth about $3,750,000. Finally, State Street Corp lifted its position in shares of Lexicon Pharmaceuticals by 3.1% during the 1st quarter. State Street Corp now owns 1,641,167 shares of the biopharmaceutical company’s stock worth $23,536,000 after purchasing an additional 49,802 shares during the last quarter.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.